A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Latest Information Update: 05 Aug 2025
At a glance
- Drugs IMVT-1402 (Primary)
- Indications Sjogren's syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Immunovant
Most Recent Events
- 18 Jul 2025 Status changed from not yet recruiting to recruiting.
- 29 May 2025 According to an Immunovant media release, the trial expected to start in summer 2025.
- 13 May 2025 Status changed from planning to not yet recruiting.